Does the Treatment of Huntington's Disease Represent a Commercial Opportunity?
Decision Resources, Inc, August 2007, Pages: 22
Huntington’s disease (HD) is a genetic neurological disorder characterized by uncontrolled body movements and cognitive dysfunction. No drugs are approved to treat the disorder, leaving a high level of unmet need.
Commercial opportunity abounds, but the small patient population deters some companies. However, because of novel treatment approaches, interest in HD research is growing and companies may be able to tap into the enormous commercial potential, especially if a drug can treat multiple neurological diseases.
Questions Answered in This Spectrum Report:
-Huntington’s disease has a small patient population across all markets. What are the advantages and disadvantages for drug developers? What effect does orphan-drug status have on a drug’s potential?
-No therapies are approved specifically for HD; all current therapies are used off-label and provide only symptomatic relief. Which drugs are being investigated in clinical trials? What are the difficulties? When will a drug launch for HD?
-Novel treatment approaches including disease-modifying stem-cell and gene therapies are making some headway. What companies are investigating HD treatments and what are the most promising treatment approaches? At what stage are these treatments, and what are the chances of their launching for HD?
Scope:
-Overview of Huntington’s disease: genetics, pathophysiology, epidemiology, symptoms, and diagnosis.
-Current treatment approach: no therapies are approved for HD; several drugs are used off-label to treat symptoms.
-Emerging therapies: disease-modifying agents, including Amarin’s Miraxion (Phase III) and Avicena’s HD-02 (Phase II), and symptomatic therapies, including Prestwick’s Xenazine (preregistered) and NeuroSearch’s ACR-16 (Phase II).
-Novel treatment approaches: stem-cell transplantation and gene therapy.
-Challenges and outlook: the future of the HD market.
Executive Summary
Strategic Considerations
Stakeholder Implications
Introduction
Overview of Huntington’s Disease
The Genetics of Huntington’s Disease
Pathophysiology
Disease Onset, Symptoms, and Diagnosis
Epidemiology and Orphan Disease Status
Current Treatment Strategies
Emerging Therapies
Disease-Modifying Agents
Amarin’s Miraxion
Avicena’s HD-02
MethylGene and EnVivo’s Phenylbutyrate
Neurotrophic Factors: BDNF, GDNF, CNTF
Symptomatic Emerging Therapies
Prestwick Pharmaceuticals’ Xenazine
NeuroSearch’s ACR-16
Sanofi -Aventis’s Rilutek
Medivation’s Dimebon
Challenges and Opportunities
Tables:
1 Inheritance Patterns of Huntington’s Disease
2 Effect of CAG Repeats on Huntington’s Disease Development
3 Agents in Commercial Development for the Treatment of Huntington’s Disease
4 Agents Under Academic Investigation for the Treatment of Huntington’s Disease
Figures:
1 Brain Structures Implicated in Huntington’s Disease
2 Prevalence of Huntington’s Disease in Select Geographic Regions
Sidebars:
Novel Approaches to the Treatment of Huntington’s Disease: Stem-Cell Transplantation
Novel Approaches to the Treatment of Huntington’s Disease: Gene Therapy
-Abbott
-Amarin
-Amgen
-AstraZeneca
-Avicena
-Bristol-Myers Squibb
-Carlsson Research
-Ceregene
-Edison Pharmaceuticals
-Eli Lilly
-Endo Pharmaceuticals
-EnVivo
-Janssen
-Medivation
-MethylGene
-NeuroSearch
-Novartis
-Pfizer
-Prestwick Pharmaceuticals
-Renovis
-Sanofi -Aventis
-Wyeth
Products Mentioned:
-ACR-16
-Amantadine (Symmetrel)
-Artane (trihexyphenidyl)
-Atomoxetine (Strattera)
-CERE-120
-Citalopram (Celexa)
-CoEnzyme Q10
-Depakene (valproic acid)
-Depakote (valproic acid and divalproex
sodium)
-Dimebon
-HD-02
-Memantine (Namenda)
-Minocycline
-Miraxion
-NXY-059
-Phenylbutyrate
-Prozac (fl uoxetine)
-Rilutek (riluzole)
-Risperdal (risperidone)
-SER-AP-ES (reserpine)
-Seroquel (quetiapine)
-Sinemet (levodopa)
-Xenazine (tetrabenazine)
-Zoloft (sertraline)
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
